鹭燕医药
(002788)
| 流通市值：31.60亿 | | | 总市值：32.17亿 |
| 流通股本：3.82亿 | | | 总股本：3.89亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 15,413,532,406.63 | 10,306,033,349.96 | 5,135,680,997.86 | 19,845,534,615.24 |
| 营业收入 | 15,413,532,406.63 | 10,306,033,349.96 | 5,135,680,997.86 | 19,845,534,615.24 |
| 二、营业总成本 | 15,050,903,211.4 | 10,042,759,659.11 | 5,015,345,024.95 | 19,359,450,781.01 |
| 营业成本 | 14,281,433,662.95 | 9,534,887,241.86 | 4,757,525,388.33 | 18,336,470,188.47 |
| 税金及附加 | 34,074,119.91 | 23,290,358.59 | 11,037,807.51 | 43,549,511.38 |
| 销售费用 | 341,694,741.81 | 224,483,488.13 | 114,820,698.65 | 441,712,880 |
| 管理费用 | 234,673,637.54 | 154,205,353.75 | 78,011,484.36 | 309,275,092.96 |
| 研发费用 | 3,635,551.77 | 2,737,832.1 | 1,217,913.27 | 5,534,269.41 |
| 财务费用 | 155,391,497.42 | 103,155,384.68 | 52,731,732.83 | 222,908,838.79 |
| 其中:利息费用 | 152,951,908.08 | 101,711,285.65 | 50,776,018.56 | 222,852,936.19 |
| 其中:利息收入 | 3,012,156.36 | 2,097,047.95 | 1,040,779.9 | 5,142,020.27 |
| 加:公允价值变动收益 | - | - | 0 | - |
| 加:投资收益 | -12,979,289.94 | -9,313,276.97 | -3,551,142.87 | -12,155,845.85 |
| 净敞口套期收益 | - | - | 0 | - |
| 资产处置收益 | 67,986.37 | -25,147.59 | -3,612.5 | 275,980.87 |
| 资产减值损失(新) | -289,948.89 | 418,827.59 | -575,385.33 | -2,580,405.71 |
| 信用减值损失(新) | -17,520,254 | -14,859,006.99 | -12,280,456.9 | -14,714,043.7 |
| 其他收益 | 5,285,128.14 | 5,722,376.2 | 1,595,980.44 | 11,646,956.64 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 337,192,816.91 | 245,217,463.09 | 105,521,355.75 | 468,556,476.48 |
| 加:营业外收入 | 1,361,343.06 | 1,117,822.66 | 246,552.02 | 2,652,324.38 |
| 减:营业外支出 | 4,749,735.65 | 1,182,106.04 | 227,063.14 | 1,787,077.39 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 333,804,424.32 | 245,153,179.71 | 105,540,844.63 | 469,421,723.47 |
| 减:所得税费用 | 75,903,320.59 | 54,388,975.52 | 22,016,434.91 | 104,927,350.84 |
| 六、净利润 | 257,901,103.73 | 190,764,204.19 | 83,524,409.72 | 364,494,372.63 |
| 持续经营净利润 | 257,901,103.73 | 190,764,204.19 | 83,524,409.72 | 364,494,372.63 |
| 归属于母公司股东的净利润 | 257,346,811.41 | 190,373,536.68 | 83,776,431.42 | 363,530,313.01 |
| 少数股东损益 | 554,292.32 | 390,667.51 | -252,021.7 | 964,059.62 |
| (一)基本每股收益 | 0.66 | 0.49 | 0.22 | 0.94 |
| (二)稀释每股收益 | 0.66 | - | - | - |
| 八、其他综合收益 | -67,892.15 | 1,093,908.95 | 5,174.94 | 1,017,731.35 |
| 归属于母公司股东的其他综合收益 | -67,892.15 | 1,093,908.95 | 5,174.94 | 1,017,731.35 |
| 九、综合收益总额 | 257,833,211.58 | 191,858,113.14 | 83,529,584.66 | 365,512,103.98 |
| 归属于母公司股东的综合收益总额 | 257,278,919.26 | 191,467,445.63 | 83,781,606.36 | 364,548,044.36 |
| 归属于少数股东的综合收益总额 | 554,292.32 | 390,667.51 | -252,021.7 | 964,059.62 |
| 公告日期 | 2024-10-22 | 2024-08-22 | 2024-04-16 | 2024-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |